Together, we can transform the future of cancer care.
Tracking early stage breast cancer with ultrasensitive ctDNA
Information for patients with breast cancer
Monitoring therapy response with ultrasensitive ctDNA across cancer types
Ultrasensitive ctDNA detection in early-stage lung cancer
Personalis is transforming the development of next-generation therapies.
When you have better insights into each patient’s cancer, you can provide earlier and more optimized treatment. We’re working toward a future where the most advanced and discerning genomic testing can transform cancer care.
Uncover deeper insights with a CGP test that unlocks the entire exome and transcriptome with matched tumor-normal analysis.
Get more clarity from a powerful residual disease (MRD) and early recurrence detection test. NeXT Personal reached ~1 Part Per Million (PPM) detection threshold (LOD50) in the analytical validation.1
Through our financial assistance program, we work with qualifying patients to reduce or eliminate their out-of-pocket costs, so they can focus on their fight against cancer.
See how our streamlined sample collection and billing processes are making advanced genomic testing a reality for an increasing number of cancer patients.
